


Tardive Dyskinesia

The lifetime prevalence of TD in patients treated with traditional dopamine receptor-blocking drugs is



Source: Kenney C, Hunter C, Davidson A, Jankovic J. Metoclopramide, an increasingly recognized cause of tardive dyskinesia. *J Clin Pharmacol.* 2008;48:379-384

Comparison of 1st- and 2nd-Generation Antipsychotics

In a meta-analysis of randomized controlled studies of 1st- and 2nd-generation antipsychotics


2.2% of patients treated with SGAs developed TD

6.3% of patients treated with FGAs developed TD

Carbon M, Hsieh C-H, Kane J, Correll C. Meta-analysis of tardive dyskinesia rates in randomized controlled studies comparing first- to-second-generation antipsychotics. *Schizophr Bull.* 2017;43(Suppl 1):S71.

Gender Disparity in Development of Tardive Dyskinesia

When treated with neuroleptics



Yassa R, Jeste DV. Gender differences in tardive dyskinesia: A critical review of the literature. *Schizophr Bull.* 1992;4:701-715.